• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

LPBI Group’s History

LPBI Group’s History

For 2019 – 2020 click on 2019 VISTA

https://pharmaceuticalintelligence.com/2019-vista/

 

 

Year End 2016 Statement on Yearly Progress by LPBI Group

Curator: Aviva Lev-Ari, PhD, RN

LPBI Group has Three Enterprise Types and Five Subsidiaries as described, below.

pharma_bi-background0238 copy

 Image Source: Google Images

We are in Knowledge-based Informational Services

Line-of-Business #1:

Open Access OnLine Scientific Journal  

  • 1,121,301 e-Readers, Site Statistics on 12/26/2016 

June 19, 2016 – We Celebrate reaching over One Million e-Readers @PharmaceuticalIntelligence.com

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

  • 5,005 Scientific Articles, Site Statistics on 12/26/2016 

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

Curator and Open Access Journal Editor-in-Chief: Aviva Lev-Ari, PhD, RN

 

  • Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Curator: Aviva Lev-Ari, PhD, RN

 

  • 7,267 Comments by Scientists, Site Statistics on 12/26/2016 
  • 2,183 Subscribers, Site Statistics on 12/26/2016

 

Line-of-Business #2:

BioMed e-Series, Five Series in Medicine, 8 e-Books on Amazon.com, 7 e-Books in 2017

  • New e-Book TITLES forthcoming on Amazon.com in 2016 from LPBI Group’s BioMed e-Series –Forthcoming COVER PAGES

Editor-in-Chief, Aviva Lev-Ari, PhD, RN

 

Line-of-Business #3:

Real Time Press Coverage of BioTech Global Premier Conferences, Portfolio of ~30 events

  • Super RECORD of REAL TIME Coverage of Biotech and Medicine Conferences by LPBI Group in 2016

Curator: Aviva Lev-Ari, PhD, RN

Line-of-Business #4: No Progress in 2016

Audio-Podcast Series in Medicine, 5 tracks

&

  • Subsidiary 4: Intellectual Property Asset Management

Line-of-Business #5: New Patents issued to Bill Zurn

Representation of US Patent Holders for Commercialization, Licensing and Partnerships

We are in Research Biotech Businesses

 

  • Subsidiary 3: R&D in 3D BioPrinting

Line-of-Business #6:

Tissue Engineering, Gene Therapy: Stem Cells & Gene Editing, Medical Devices: Product Concepts

  • 3D Medical BioPrinting Technology Reporting by Irina Robu, PhD – a forthcoming Article in “Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices”

Curator: Aviva Lev-Ari, PhD, RN

 

  • Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices

Editors: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

&

  • Subsidiary 5: Pharmaceutical R&D: Drug Discovery and Drug-Devices Development

Line-of-Business #7:

  • Drug Discovery with 3D BioPrinting

Team developing new mechanism of action for Therapeutics and Diagnostics for Early Detection of Pancreatic Cancer

 

Line-of-Business #8:

  • Drug Delivery System – One solution for many agents for many indications

Team developing solutions with Nanoparticles and with Exosomes 

We are in Business Financial Transactions (No Securities Traded)

 

  • Subsidiary 2: Funding Early Stage Businesses, IP Licensing and Business Partnerships:

Line-of-Business #9:

Early Stage Venture Funding

MEDICAL DEVICES

Pharmaceutical Informational PLATFORMS

INVENTIONS IN BIOLOGICS

Representation of 13 ventures for the purpose of prospecting for funding. Seeking business partner to developing FUNDING of the following Ventures, if interested to further explore jointly, please e-mail me:

avivalev-ari@alum.berkeley.edu

 

  • LPBI Group’s Portfolio of Clients include the following:

 

  1. Woodland Pharmaceutical

https://gust.com/companies/woodland_pharmaceuticals

 

  1. BioTerm Pharmaceuticals

http://www.bio-term.com/

 

  1. Akshaya Bio Inc. – Portfolio of 28 Patents in vaccine – viral infection

http://www.akshayabio.com/

 

  1. ValveCure.com

http://www.valvecure.com/Home.html

 

  1. Alpha Sensors, Inc.

http://alphaszenszor.com/

 

  1. AlphaIP, Inc.

http://www.alphaip.net/

 

  1. SBH Sciences, Inc

http://www.sbhsciences.com/

 

  1. Telerescue

http://www.telerescue.co.il/

 

  1. New Medicine, Inc.

http://www.newmedinc.com/

 

  1. LPBI Group – Aviva Lev-Ari, PhD, RN – Founder

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/

 

10a. DrugDiscovery @LPBI Group – Aviva Lev-Ari, PhD, RN – Co–Founder and Raphael Nir, PhD – Co–Founder

https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/

 

  1. Portfolio of Patents of S.Y. in Anti-Inflammatory, A Macro Molecule of a Multifunctional NSAID – Portfolio of 13 US Patents

Multi-Functional Anti-Inflammatory Drugs (MFAIDs): Small Molecule Invention of Dr. Saul Yedgar, HUJI and Yissum

 

  1. Portfolio of Patents under management of Y. M.

 

  1. Vyriad – Oncolytic Virotherapy for the Treatment of Cancer
    Vyriad – http://www.vyriad.com/

 

In Preparation: VB Profile

http://pages.vbprofiles.com/TheMostPopularLists

 

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

This page has the following sub pages.

  • LPBI Group’s Vision
  • Subsidiary 1: Leaders in Pharmaceutical Business Intelligence (LPBI) – Scientific Digital MEDIA
  • Subsidiary 2: Deals, Funding & Partnerships – DFP
  • Subsidiary 3: Medical 3D BioPrinting – M3DP
  • Subsidiary 4: US Patents & International Patents – Commercialization, Licensing & Sales (USPat)
  • Subsidiary 5: Joint Ventures for IP Development – JVIP
  • EXPLORATION INTO FIRST ROUND OF INVESTMENT FOR LPBI Group
  • 2016 Strategic Plan for LPBI Group

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    %d bloggers like this: